Opinion|Videos|February 25, 2025

Data With IL-13– Targeting Agents in Atopic Dermatitis in Clinical Practice

Panelists discuss switching from dupilumab to other IL-13 inhibitors in atopic dermatitis (AD), reviewing real-world data (RWD) on the effectiveness, safety, and patient outcomes associated with these treatments.

Video content above is prompted by the following:

  • Can you talk about switching from dupilumab and other RWD with IL-13 agents in AD?

Latest CME